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SUMMARY. Immunomodulators that induce local endoge-
nous interferon-alpha (IFN-a) production by plasmacytoid
dendritic cells (pDCs) may offer new strategies for the
treatment of patients chronically infected with the
hepatitis C virus (HCV). However, such an approach may be
compromised if reports are true that IFN-a production by
pDCs from patients with chronic HCV (cHCV) is profoundly
impaired. To address the question of pDC dysfunction in
cHCV more deﬁnitively, in the present study a panel of four
prototypic synthetic agonists of toll-like receptor 7 (TLR7) or
TLR9 were administered in vitro to pDCs puriﬁed from cHCV
patients and from normal uninfected donors and their
responses compared in terms of not only IFN-a production
but also the global expression of other cytokines and phe-
notypic maturation. Plasmacytoid DCs from uninfected do-
nors produced substantial levels of IFN-a in response to three
of the four agonists and yet only one TLR9 agonist, a class C
CpG oligodeoxynucleotide (ODN), induced robust IFN-a
production by pDCs from cHCV patients. Proinﬂammatory
cytokine production and phenotypic maturation in response
to all four agonists was equivalent in infected and uninfected
pDCs. These data point to a profound but selective defect in
IFN-a production by pDCs from cHCV donors. Nonetheless,
a class C CpG ODN successfully induced robust IFN-a
production, suggesting that this class of TLR9 agonist may
have utility as a future immunotherapeutic for the treatment
of chronic HCV infection.
Keywords: CpG, dendritic cell, hepatitis C, interferon-a,
plasmacytoid, toll-like receptor.
INTRODUCTION
The hepatitis C virus (HCV) is a blood-borne, hepatotrophic
viruswhichestablisheschronicHCV(cHCV)infectioninupto
85% of cases. With an estimated 2% of the global population
infected with HCV [1], the potential for chronic infection to
lead to cirrhosis, end-stage liver disease and hepatocellular
carcinoma, poses a considerable health burden.
The mainstay of current therapies for cHCV is interferon
alpha (IFN-a), a type 1 interferon typically administered as
pegylated, single-species IFN-a2 in combination with the
antiviral ribavirin. IFN-a has multiple antiviral actions [2]. It
induces genes that inhibit viral replication [3] and boosts the
innate andadaptive immune response, activating NK cells [4]
and myeloid DCs [5] respectively. IFN-a also promotes the
development of a polarized antigen-speciﬁc type 1 T-cell
response [6,7] thought to favour resolution of HCV infection
[8] and pDC-derived IFN-a supports the induction of CD8
+
T cell responses [9]. Nonetheless, combined pegylated IFN-
a2 ⁄ ribavirin therapy succeeds in only 42–46% of HCV
genotype1infectionsand76–80%ofgenotype2 ⁄ 3infections
[2]. Furthermore, the raised systemic levels of IFN-a can lead
to psychiatric and other adverse events necessitating pre-
mature cessation of treatment in approximately 10% of cases
[10]. Alternative novel strategies for the treatment of cHCV
are therefore required.
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ulators to induce endogenous, local IFN-a production by
plasmacytoid dendritic cells (pDCs). In response to viral
infection, pDCs are stimulated to migrate to lymph nodes
where they produce large amounts of type I interferon
(IFN-a, IFN-b, IFN-x and IFN-k) and a broad spectrum of
IFN-a subtypes [11–13]. Plasmacytoid DCs sense viral
infection through innate pattern recognition receptors of the
toll-like receptor (TLR) family, speciﬁcally TLR7 and TLR9
[14]. Upon ligation, TLR7 and TLR9 trigger a cascade of
shared intracellular signalling events which culminate in
abundant IFN-a production together with enhanced pro-
duction of other cytokines and pDC maturation [15,16].
Thus, TLR7 or TLR9 may be appropriate pharmacological
targets for immunomodulation of IFN-a production by pDCs,
with the diverse range of endogenous type I IFN species
produced offering an advantage over the administration of
an exogenous single species of IFN-a.
The natural ligands for TLR7 are patterns within viral
single-stranded RNAs [17] but synthetic ligands including
imidazoquinolines [18] and guanosine analogues [19] are
also recognized. TLR9 recognizes unmethylated CpG dinu-
cleotide-richsequenceswithinbacterialandviralDNA,which
can be mimicked by synthetic CpG oligodeoxynucleotides
(ODNs) [20]. Three categories of CpG-ODNs have been iden-
tiﬁed: classes A (or D), B (or K) and C. CpG-A ODNs favour
IFN-a production over pDC differentiation and are poor B-cell
activators, whereas CpG-B ODNs show the converse [21].
CpG-CODNscombinestrongIFN-ainductionandefﬁcientpDC
maturation [22,23] and efﬁciently stimulate B cells.
A possible hurdle to using TLR7 or TLR9 agonists as
inducers of endogenous IFN-a production in cHCV are reports
that pDCs derived from cHCV patients are profoundly
impaired in their ability to produce IFN-a upon in vitro
stimulation [24–31]. However, other studies have found
IFN-a production by cHCV–pDCs to be intact [32–35].
Therefore, the purpose of the current study was to use a panel
of prototypic synthetic TLR7 and TLR9 agonists to determine
if normal function can successfully be induced in pDCs taken
from cHCV subjects. The TLR7 agonists selected were
loxoribine (a guanosine analogue) and imiquimod (an
imidazoquinoline). The TLR9 agonists were the class A CpG,
ODN2216 [36] and the class C CpG, M362 [22]. The function
of pDCs puriﬁed from chronically-HCV infected and normal,
uninfected subjects was investigated not only in terms of
IFN-a production, but also with respect to the production of a
range of other cytokines and pDC maturation.
MATERIALS AND METHODS
Study subjects
Ethical approval was obtained from Southampton and South
West Hampshire Joint Research Ethics Committee. Thirty-
seven patients with detectable HCV RNA and a clinical
diagnosis of cHCV disease were recruited from hepatology
clinics run by Southampton University Hospitals NHS Trust.
All gave written informed consent. Patients treated for HCV
within the preceding 6 months or known to be coinfected
with another blood-borne virus were excluded from the
study. Table 1 summarizes the clinical characteristics of the
cHCV patients and the 25 normal healthy donors (NHD)
used as controls. NHD subjects had no known risk factors for
blood-borne virus infection.
Plasmacytoid DC preparation
Peripheral blood mononuclear cells (PBMCs) were separated
from fresh EDTA-anticoagulated blood obtained from cHCV
patients (typically 25–50 mL) or uninfected subjects
(100–400 mL), by Lymphoprep (Robbins Scientiﬁc, Solihull,
Table 1 Subject clinical characteristics
Characteristics
cHCV
patients
(n = 37)
Normal
healthy
subjects
(n = 25)
Age (years);
mean (range)
49 (36–75) 48 (23–75)
Gender (M ⁄ F) 27 ⁄ 10 20 ⁄ 5
ALT (IU ⁄ L);
mean (range)
88 (18–278) N ⁄ A
HCV viral
load (IU ⁄ mL);
mean (range)*
4.86 · 10
6
(1.02 · 10
4
)3.01 · 10
7)
N ⁄ A
Genotype

12 0 N ⁄ A
2 ⁄ 31 3
41
Non-1 3
Disease severity

Mild 16 N ⁄ A
Mild ⁄ moderate 4
Moderate 10
Severe (+cirrhosis) 7 (6)
Treatment
naı ¨ve ⁄ non-responder
24 ⁄ 13 N ⁄ A
*Viral load determined for 31 patients by quantitative
PCR (Cobas Amplicor HCV Monitor test; Roche Molecular
Systems, Pleasanton, CA, USA). In the remaining six
patients, presence of HCV virus was conﬁrmed using a
qualitative PCR assay.
HCV genotype determined using PCR-based Genotyping for
Treatment Assay (iQur Ltd, Southampton, UK), with
exception of non-1 samples which used a superceded assay.
 Based on histological analysis of biopsies for inﬂammation
and ﬁbrosis. In the absence of histological evidence, disease
status was determined by clinical criteria including physical
examination, diagnostic imaging and laboratory indices.
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316 N. A. Libri et al.UK) density gradient centrifugation. Plasmacytoid DCs
(89–95% pure) were isolated from PBMCs by positive
immunomagnetic selection with anti-CD304 (BDCA-4)-
coated immunomagnetic beads (Miltenyi Biotec, Bisley, UK).
Stimulation of plasmacytoid DCs
Freshly-isolated pDCs (2 · 10
5 ⁄ mL) in complete RPMI
medium [RPMI 1640 without phenol red with 2 mML -glu-
tamine, 100 U ⁄ mL penicillin, 100 lg ⁄ mL streptomycin
(all Invitrogen Ltd, Paisley, UK) and 10% heat-inactivated
FCS (Hyclone, Perbio Science UK Ltd, Tattenhall, UK)]
were plated into 96-well (200 lL ⁄ well) or 48-well
(500 lL ⁄ well) plates, depending on cell yields. pDCs were
cultured alone or with CpG-A (ODN 2216, [36]), ODN 2216
control (GpC control for ODN2216), CpG-C (M362, [22]),
loxoribine or imiquimod at the concentrations indicated in
the text. All TLR agonists were from InvivoGen (San Diego,
CA, USA) and were reconstituted in endotoxin-free water.
After 20–24 h incubation at 37  Ci n5 %C O 2, cell-free su-
pernatants were collected and frozen pending cytokine
analysis and ⁄ or pDCs were retained for phenotypic analysis.
Quantifying cytokine production
Secreted IFN-a was measured using a human IFN-a multi-
species ELISA (PBL Biomedical Laboratories, Piscataway, NJ,
USA) which recognizes 13 of 14 IFN-a isoforms, the excep-
tion being IFN-aF. The manufacturers extended range
protocol was followed.
Human IFN-c, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10,
IL-12p70 and TNF-a were measured in pDC culture super-
natants using a multiplex ﬂuorescent bead immunoassay
(Bender MedSystems, Vienna, Austria). Supernatants were
incubated in 96-well ﬁlter plates with a cocktail of analyte-
speciﬁc beads and biotinylated secondary antibodies,
according to the manufacturers standard procedures,
followed by detection with streptavidin-PE. The mean ﬂuo-
rescence intensity (MFI) of 3000 bead events was measured
using a FACSCalibur ﬂow cytometer with CellQuest software
(BD Biosciences, Oxford, UK). Analyte concentration was
determined by reference to a standard curve.
Phenotypic analysis of plasmacytoid DCs
Cells in PBS containing 0.1% NaN3, 1% BSA and
100 lg ⁄ mL human IgG (Jackson Immunoresearch, West
Grove, PA, USA) were blocked for 15 min on ice then
labelled with monoclonal antibodies against HLA-DR FITC
(clone L243), CD86-FITC (clone FUN-1), CD83-APC (clone
HB15e) (all from BD Biosciences) or CD303-APC (BDCA2,
clone AC144; Miltenyi Biotec) or with isotype controls
[murine IgG1 (clone MOPC 31, APC or FITC conjugated) or
IgG2a FITC (clone G155-178) (all from BD Biosciences)].
After staining, pDCs were washed, ﬁxed in 1% formaldehyde
and stored on ice in the dark pending data acquisition using
a FACSCalibur ﬂow cytometer. MFI values for cell surface
marker staining were ﬁrst corrected by subtracting the MFI
values of the relevant isotype controls. Data are expressed
as the fold change in corrected MFI between unstimulated
and agonist-stimulated cells.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
version 4.0 for Windows (GraphPad Software, San Diego,
CA, USA). Having veriﬁed that the data were normally
distributed, statistically signiﬁcant differences between the
mean responses of NHD and cHCV subjects and between
the mean responses to agonist stimulation, were determined
using two-way anova, with Bonferroni post-tests.
RESULTS
Depressed IFN-a production by pDCs from patients with
chronic HCV-infection
Plasmacytoid DCs circulate in the blood at low frequency
and pDC numbers may be further reduced in cHCV infection
[25,27]. With low volumes of cHCV blood (‡25 mL), pDC
numbers would be insufﬁcient to use each TLR agonist at a
range of doses. Therefore, the optimal dose for IFN-a
induction by each agonist was ﬁrst determined using NHD–
pDCs. For CpG-C, 1 lm was selected as the optimal dose since
it induced maximal levels of IFN-a which declined sharply at
higher concentrations of CpG-C (Fig. 1). By contrast, IFN-a
levels declined steadily with decreasing concentrations of
CpG-A, falling off more markedly below 1 lm (Fig. 1).
Therefore, 1 lm was also selected as the optimal working
concentration for CpG-A, in line with published studies in
both NHD- [21,37] and cHCV-pDCs [25,29,35]. Based on
their stimulation of IFN-a release by NHD-pDCs, 250 lm
loxoribine and 5 lm imiquimod were selected as optimal
working concentrations (Fig. 1).
Puriﬁed pDCs from cHCV patients and uninfected volun-
teers were cultured for 20–24 h alone or with 1 lm CpG-A,
1 lm CpG-C, 250 lm loxoribine or 5 lm imiquimod. In
preliminary experiments, an equimolar amount of control
CpG-A ODN in which all CpG dinucleotides were reversed
was included. NHD–pDCs released negligible levels of IFN-a
when cultured alone (30.51 ± 7.00 pg ⁄ 10
5 cells, Fig. 2) or
with the control ODN (11.90 ± 4.60 pg ⁄ 10
5 cells, data not
shown). Compared to the medium-only control, CpG-A,
CpG-C and loxoribine induced signiﬁcant levels of IFN-a
(Fig. 2 and legend) and were of similar potency, whereas
imiquimod stimulated only weak IFN-a production to levels
that were not statistically signiﬁcant.
In striking contrast, in HCV infection, statistically signiﬁ-
cant IFN-a production by cHCV-pDCs was only induced by
CpG-C (Fig. 2), reaching levels equivalent to those induced
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A CpG-C induces IFN-a production by pDCs in cHCV 317in uninfected pDCs. Compared to NHD-pDCs, IFN-a produc-
tion by cHCV-pDCs was signiﬁcantly depressed in response
to CpG-A and loxoribine (Fig. 2) with mean levels of IFN-a
production by cHCV-pDCs 94.6% lower in response to CpG-A
and 76.9% lower in response to loxoribine. In response to
imiquimod, although cHCV–pDCs produced mean levels of
IFN-a 84.2% below normal (NHD, 4266 ± 1665; cHCV,
675.6 ± 180.1), the difference between the two subject
groups was not statistically signiﬁcant (P > 0.05).
Dividing the cohort of cHCV patients into those who had
failed to respond to previous treatment with IFN-a2 ⁄ riba-
virin (non-responders, NR) and patients who had not yet
received treatment (treatment naı ¨ve), no signiﬁcant differ-
ence was found between the two groups in terms of mean
IFN-a production in response to CpG-A, CpG-C or loxoribine
[CpG-A: NR (n = 7), 364.3 ± 121.4 vs naı ¨ve (n = 13),
877.8 ± 453.6, P = 0.4271; CpG-C: NR (n = 7), 10720 ±
3455 vs naı ¨ve (n = 13), 7015 ± 3033, P = 0.4558;
loxoribine: NR (n = 9), 1537 ± 613.0 vs naı ¨ve (n = 11),
2606 ± 1199, P = 0.4680]. Thus, both patient subsets
failed to respond to CpG-A and loxoribine, but mounted
robust IFN-a production following stimulation with CpG-C.
Cytokine production by pDCs from patients with chronic
HCV-infection is not globally impaired
Although IFN-a is the principle cytokine produced by pDCs,
they can also produce TNF-a, IL-6 and IL-8 and in some
cases, IL-12 and IL-10. Using a multiplex assay, these
cytokines were analysed in the same supernatants used for
IFN-a measurements. In both NHD- and cHCV–pDCs, only
TNF-a was signiﬁcantly induced above control levels and
only in response to the CpG-C ODN (Fig. 3). Comparing TNF-
a production by pDCs from the two subject groups for indi-
vidual TLR agonists, the mean levels of TNF-a production did
not differ signiﬁcantly (Fig. 3) although there was a consis-
tent trend for TNF-a to be expressed at higher levels by
cHCV- than NHD-pDCs (Fig. 3).
In both NHD- and cHCV-pDCs, release of IL-6, IL-8 and
IL-10 was enhanced by some TLR agonists, but these in-
creases were not statistically signiﬁcant (Table 2). In terms
of IL-6 and IL-10 production, cHCV- and NHD–pDCs func-
tioned equally but basal and induced levels of IL-8 expres-
sion were consistently, although non-signiﬁcantly, higher in
cHCV- than NHD-pDCs (Table 2). IL-12 was not induced by
any of the agonists (data not shown).
In vitro immunophenotypic maturation of pDCs is not
impaired in cHCV infection
Upon stimulation, as well as producing type I IFN, pDCs
differentiate into mature DCs capable of antigen presentation
[38]. To determine if pDCs from cHCV patients undergo
normal immunophenotypic maturation in response to TLR7
and TLR9 agonists, changes in expression of CD86, HLA-DR,
CD83 and BDCA-2 were measured.
Fig. 1 IFN-a production by NHD-pDCs
in response to TLR7 and TLR9 agonist
dose. Puriﬁed pDCs from three unin-
fected donors were stimulated for 24 h
with a dose range of CpG-A or CpG-C.
NHD-pDCs from a further four donors
were stimulated with loxoribine or
imiquimod. Secreted IFN-a was
measured using a multi-subtype ELISA.
The optimal dose of each agonist was
determined and is stated in the text.
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318 N. A. Libri et al.After 20–24 h of stimulation, phenotypic maturation
was equivalent for NHD- and cHCV–pDCs (Fig. 4). The
extent of CD86 upregulation did not differ signiﬁcantly
between NHD- and cHCV–pDCs in response to CpG-A
(2-fold), CpG-C (8- to 10-fold), loxoribine (6-fold) and
imiquimod (6-fold) (Fig. 4a). CpG-C was the stongest
stimulus for CD86 upregulation, being signiﬁcantly more
potent than CpG-A in both subject groups and more
effective than loxoribine in cHCV–pDCs. Irrespective of
whether the responding pDCs were derived from HCV-in-
fected or uninfected subjects, all four agonists induced a
slight (1.5-fold) upregulation of HLA-DR and a 2- to 5-fold
increase in cell surface CD83 (data not shown).
BDCA-2 was downregulated from the cell surface by all
four agonists, with CpG-C again being the most potent,
causing signiﬁcantly stronger downregulation than CpG-A
in both NHD- and cHVC-pDCs (Fig. 4b). There was a trend
for BDCA-2 downregulation to be less pronounced on
cHCV–pDCs but for individual agonists, the difference in
response between NHD- and cHCV–pDC was not signiﬁ-
cant (Fig. 4b).
Higher doses of the CpG-A ODN increase IFN-a production
by cHCV–pDCs
In NHD–pDCs, increasing the dose of a class A CpG can
augment IFN-a production over a considerably wider con-
centration range than for CpG-C ODNs (Fig. 1 and [23]).
Therefore, in nine cHCV subjects, puriﬁed pDCs were stim-
ulated with 1 lm CpG-C and with 1, 5 and 10 lm CpG-A.
Again, 1 lm CpG-A failed to induce IFN-a production to the
levels achieved by an equimolar amount of the class C CpG
ODN (Fig. 5). However, increasing the CpG-A dose to 5 lm
induced IFN-a as efﬁciently as 1 lm CpG-C whilst a further
increase to 10 lm CpG-A did not further enhance IFN-a
production.
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Fig. 2 Deﬁcit in TLR7 and TLR9-induced IFN-a production
by pDCs in chronic HCV infection. Puriﬁed pDCs from
uninfected (NHD, solid bars) and HCV-infected (cHCV, open
bars) donors were stimulated for 20–24 h with medium
alone(NHD,n = 19;cHCV,n = 25)orwith1 lmCpG-AODN
(NHD, n = 13; cHCV, n = 20), 1 lm CpG-C ODN (NHD,
n = 15; cHCV, n = 20), 250 lm loxoribine (NHD, n = 17;
cHCV, n = 20) or 5 lm imiquimod (NHD, n = 16; cHCV,
n = 17) and secreted IFN-a assayed using a multi-subtype
ELISA. Bars represent means ± SEM. Compared to culture in
theabsenceofaTLRagonist(medium),NHD–pDCsproduced
signiﬁcant quantities of IFN-a in response to CpG-A
(P < 0.001),CpG-C(P < 0.001)andloxoribine(P < 0.001).
IFN-a production upon stimulation with the TLR9 agonists
wassigniﬁcantlyhigherthanfollowingimiquimodtreatment
(CpG-A > imiquimod, P < 0.01; CpG-C > imiquimod,
P < 0.01). Robust IFN-a production by cHCV–pDCs only
occurred in response to CpG-C, reaching levels signiﬁcantly
higher than any other treatment (CpG-C > medium,
P < 0.001; CpG-C > CpG-A, P < 0.01; CpG-C > loxoribine,
P < 0.05; CpG-C > imiquimod, P < 0.01). Signiﬁcant
differences in the response to individual agonists are shown
on the graph: CpG-A, cHCV-pDCs < NHD-pDCs,
***P < 0.001; loxoribine, cHCV–pDCs < NHD–pDCs,
*P < 0.05. The response of NHD– and cHCV–pDCs to CpG-C
did not differ signiﬁcantly (n.s., P > 0.05) nor to imiquimod
(P > 0.05) or medium (P > 0.05).
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Fig. 3 TLR7 and TLR9 agonists induce normal levels of
TNF-a production in pDCs from chronically HCV-infected
subjects. pDC supernatants from a subset of the NHD and
cHCV subjects shown in Fig. 2 were additionally assayed for
the presence of TNF-a, yielding the following data sets:
medium alone (NHD, n = 10; cHCV, n = 15), 1 lm CpG-A
ODN (NHD, n = 9; cHCV, n = 9), 1 lm CpG-C ODN (NHD,
n = 9; cHCV, n = 10), 250 lm loxoribine (NHD, n = 10;
cHCV, n = 11) and 5 lm imiquimod (NHD, n = 10; cHCV,
n = 9). Bars represent means ± SEM; NHD (solid bars),
CHC (open bars). Compared to cells exposed to medium
alone, TNF-a was signiﬁcantly induced only by CpG-C
(P < 0.001). In both NHD- and cHCV-pDCs, CpG-C induced
signiﬁcantly more TNF-a than CpG-A (P < 0.001), loxori-
bine (P < 0.01) or imiquimod (P < 0.001). The response of
NHD- and cHCV–pDCs to individual agonists did not differ
signiﬁcantly (n.s.).
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By virtue of their potent secretion of type-1 interferon upon
stimulation with synthetic agonists of TLR7 or TLR9, pDCs
may be ideal targets for the induction of local, endogenous
IFN-a as a novel therapeutic strategy in the treatment
of chronic hepatitis C. However, pDCs derived from cHCV
patients appear to be profoundly impaired in their ability to
produce IFN-a upon in vitro stimulation, although these
ﬁndings are disputed. The present study aimed to address the
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Fig. 4 Immunophenotypic maturationofpDCsis notimpairedincHCVinfection. After20–24 hstimulationwithTLRagonists,
pDCs were processed for ﬂow cytometry to identify immunophenotypic changes consistent with maturation. FACS histograms
from a representative NHD and cHCV subject show (a) the rise in CD86 expression and (b) fall in BDCA-2 expression following
stimulation with CpG-C (solid histogram) compared to unstimulated cells (open histogram overlay). The bar graphs show
the average fold change in mean ﬂuorescence intensity (MFI) ± SEM of (a) CD86 and (b) BDCA-2 on pDCs from 9 NHD (solid
bars) and eight cHCV (open bars) subjects (seven NHD for TLR7 agonists) induced by the four TLR agonists. For each TLR
agonist, thedegree of(a)upregulation ofCD86and(b)downregulation ofBDCA-2didnotdiffersigniﬁcantly between NHD–pDC
and cHCV–pDCs (n.s.). CpG-C was a signiﬁcantly stronger stimulus for CD86 upregulation than CpG-A (NHD–pDCs, P < 0.001;
cHCV–pDCs, P < 0.01) and for cHCV–pDCs loxoribine was also signiﬁcantly more potent than CpG-A (P < 0.05). CpG-C
caused signiﬁcantly stronger downregulation of BDCA-2 than CpG-A (NHD–pDCs, P < 0.01; cHVC–pDCs, P < 0.01).
Table 2 Expression of IL-6, IL-8 and IL-10 in response to TLR agonists
Stimulus
IL-6 IL-8 IL-10
NHD cHCV P* NHD cHCV P* NHD cHCV P*
CpG-A 3268 ± 1399 2142 ± 664.6 n.s. 7263 ± 1437 12080 ± 2480 n.s. 365.9 ± 212.3 356.8 ± 136.3 n.s.
CpG-C 4429 ± 1467 3817 ± 1074 n.s. 9034 ± 1876 12320 ± 1631 n.s. 385.7 ± 169.7 397.7 ± 176.3 n.s.
LOXO 2545 ± 1060 1739 ± 686.1 n.s. 10380 ± 2931 14750 ± 3385 n.s. 224.6 ± 94.48 274.1 ± 137.7 n.s.
IMIQ 2292 ± 797.7 2404 ± 1320 n.s. 8354 ± 1587 15250 ± 5062 n.s. 216.7 ± 83.90 349.1 ± 147.0 n.s.
Medium 1774 ± 738.2 1555 ± 700.9 n.s. 7703 ± 1662 11410 ± 3138 n.s. 126.4 ± 47.89 144.7 ± 39.77 n.s.
Values are expressed as mean ± SEM.
*Signiﬁcance of difference between mean cytokine production by NHD and cHCV–pDCs for each TLR agonist, determined by
two-way anova with Bonferroni post-test.
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320 N. A. Libri et al.question of pDC dysfunction in cHCV more deﬁnitively, by
administering a panel of four agonists of TLR7 or TLR9 to
pDCs from patients chronically infected with HCV. The
ability of pDCs from cHCV patients to produce IFN-a upon
TLR engagement was found to be profoundly but speciﬁcally
impaired, with phenotypic maturation and the production of
other cytokines remaining unperturbed. However, one ago-
nist, a class C CpG ODN, successfully induced robust IFN-a
production by cHCV-pDCs, whilst also being a strong stim-
ulus for pDC maturation.
Of the four stimuli tested, both TLR7 agonists (loxoribine
and imiquimod) and one TLR9 agonist (the CpG A ODN)
were ineffective stimuli for IFN-a production by cHCV-pDCs
and yet in pDCs from healthy, uninfected donors, loxoribine
and the CpG-A ODN induced robust IFN-a production,
although imiquimod remained a weaker stimulus. The fail-
ure of three of the four TLR agonists to induce signiﬁcant
IFN-a release from cHCV–pDCs adds to the body of data
reporting profoundly depressed IFN-a production by cHCV–
pDCs in response to the CpG-A TLR9 agonist ODN2216
[25,27–30], the TLR7 ⁄ 8 agonist, R-848 [30] and to viral
stimuli [24,28]. However, other workers have reported
normal IFN-a production by cHCV–pDCs [32–35], even
when stimulated with the class A CpG, ODN2216.
Given that numbers of circulating pDCs are reduced in
cHCV [25,27], some of the conﬂicting ﬁndings regarding
pDC dysfunction in cHCV-patients have been attributed to
whether IFN-a production has been measured on a per cell
basis. However, this explanation is not sufﬁcient. It is par-
ticularly pertinent to compare the ﬁndings of the current
study with those of Decalf et al. [35]. Both studies stimulated
immunomagnetically puriﬁed BDCA4
+ pDCs with equivalent
concentrations of ODN2216. Decalf et al. reported normal
IFN-a production by pDCs from cHCV patients non-respon-
sive to standard IFN-a2 ⁄ ribavirin therapy, whereas in the
current study cHCV–pDCs failed to respond signiﬁcantly to
CpG-A irrespective of whether they were non-responders or
treatment naı ¨ve. The opposing ﬁndings of these two studies
may reﬂect differences in statistical power; Decalf et al.
observed highly variable levels of IFN-a production by their
cohort of non-responder cHCV patients yet only studied
seven patients. Alternatively, the contrasting results from
these two studies may be a consequence of the different
systems used to measure IFN-a. Decalf et al. used Luminex
xMAP multiplex technology for which only IFN-a2 speciﬁc
microspheres are available, whereas the current study used
a multi-subtype IFN-a ELISA, capable of detecting 14 of the
15 known human IFN-a subtypes. Since pDCs secrete mul-
tiple IFN-a subtypes [12,13,39], with different kinetics of
release [40] and differing biological activities [41], measur-
ing only one subtype may not accurately reﬂect the full
capacity of pDCs to produce IFN-a. Indeed, it would be
of interest to determine if production of particular IFN-a
subtypes is preferentially impaired in cHCV- compared to
NHD-pDCs.
The ﬁndings of the current study support the concept of
depressed IFN-a production by cHCV-pDCs, which occurs
in response to a broad spectrum of in vitro stimuli. How-
ever, for the ﬁrst time, this study shows that this defect is
not universal and can be overcome by certain stimuli,
exempliﬁed here by the prototypic class C CpG, M362. It is
particularly striking that whilst 1 lm concentrations of the
CpG-A and CpG-C ODNs, both agonists of TLR9, induced
equivalent levels of IFN-a release from NHD–pDCs, only
the CpG-C agonist could induce robust IFN-a production
by cHCV–pDCs. However, the suppressed response of
cHCV–pDCs to the CpG-A agonist was quantitative rather
than qualitative. Thus, when the in vitro dose of CpG-A
was increased, IFN-a production by cHCV–pDCs reached
the levels achieved with a lower dose of CpG-C. This
suggests that a threshold of TLR9 signalling must be
reached for robust IFN-a production and that due to the
action of unknown factors, higher doses of class A ODNs
are required to attain this threshold in cHCV–pDCs. In the
context of using CpG ODNs as in vivo therapeutics,
escalating the dose of CpG–A ODNs would be impractical
since the molecules aggregate into multimolecular assem-
blies in a manner which cannot readily be controlled or
reproduced [42].
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Fig. 5 At higher doses the CpG-A ODN stimulates efﬁcient
IFN-a production by cHCV-pDCs. Puriﬁed pDCs from nine
cHCV patients were stimulated with 1 lm CpG-C ODN (grey
bar) or 1, 5 or 10 lm CpG-A ODN (solid bars) and IFN-a
measured after 20–24 h. Bars represent means ± SEM.
IFN-a production in response to 1 lm CpG-A was signiﬁ-
cantly lower than that induced by 1 lm CpG-C (*P < 0.05).
Increasing the CpG-A concentration to 5 or 10 lm boosted
IFN-a production signiﬁcantly (5 lm CpG-A > 1 lm CpG-A,
**P < 0.01; 10 lm CpG-A > 1 lm CpG-A, **P < 0.01)
reaching levels that did not differ signiﬁcantly from those
induced by 1 lm CpG-C.
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TLR9 on pDCs leads to the release of other cytokines and to
immunophenotypic maturation [14,35]. In this study, a
multiplex ﬂow cytometric bead assay was used to analyse
proinﬂammatory cytokine production in the same superna-
tants as used for IFN-a measurement. Although the agonist
concentrations and the duration of stimulation were opti-
mized for IFN-a production, TLR ligation also upregulated
TNF-a, IL-8, IL-6 and IL-10 production to differing degrees
depending on the particular agonist. cHCV–pDCs showed a
bias for higher production of TNF-a and IL-8 than their non-
diseased counterparts and in no case did levels of cytokine
production by cHCV–pDCs fall signiﬁcantly below those of
NHD–pDCs. These ﬁndings of normal or slightly elevated
production of TNF-a, IL-6 and IL-8 by cHCV–pDCs agree with
Decalfet al.[35]althoughdeﬁcientIL-6productionbycHCV–
pDCs was reported following stimulation with the TLR7 ⁄ 8
agonist R-848 [30]. The extent of immunophenotypic matu-
ration induced by each agonist in this study was comparable
for HCV-infected and uninfected pDCs, again with the caveat
that agonist concentration and the duration of stimulation
were optimized for IFN-a production. This is fully consistent
withthematurationresponseofcHCV–pDCstoinﬂuenzavirus
[35], although in response to the TLR7 ⁄ 8 agonist, R-848,
normal upregulation of CD86 expression but impaired
upregulation of HLA-DR was reported for cHCV–pDCs [30].
Although a body of data supports the existence of
depressed IFN-a production by cHCV–pDCs, the mecha-
nism responsible for this remains to be elucidated. The
data presented here point to the defect in cHCV–pDCs
being selective, speciﬁcally impairing their ability to pro-
duce IFN-a whilst sparing proinﬂammatory cytokine
expression and differentiation towards mature APCs.
Because proinﬂammatory cytokine production and phe-
notypic maturation are unaffected, these data suggest that
TLR7 ⁄ TLR9 expression, afﬁnity and internalization are
not abnormal in cHCV–pDCs. Rather, the defect may lie in
the ability to signal IFN-a induction. In pDCs, signalling
for induction of IFN-a upon TLR7 or TLR9 ligation is
mediated by interferon-regulatory factor-7 (IRF-7) [9],
whereas expression of pro-inﬂammatory cytokines and
immunophenotypic maturation are controlled by the
coordinated actions of nuclear factor jB (NF-jB), MAP
kinase [15,16] and IRF-5 [43]. The data presented here
are consistent with a selective functional defect in
engagement of, or signalling through, the IRF-7 pathway
in cHCV–pDCs. The differential response of cHCV–pDCs to
CpG-A and CpG-C identiﬁed in this study may prove a
valuable tool in unravelling the molecular requirements
for robust IFN-a induction in cHCV–pDCs.
The data from this in vitro study lend support to the
emerging concept that in cHCV patients, pDCs are pro-
foundly impaired in their ability to produce IFN-a. However,
this need not be an insurmountable hurdle to attempts to
target pDCs therapeutically for the production of endogenous
IFN-a in HCV patients. As exempliﬁed here by the prototypic
class C CpG, M362, with careful selection agonists may be
found that can induce robust IFN-a production, proinﬂam-
matory cytokine expression and phenotypic maturation
in cHCV–pDCs. Agonists identiﬁed in vitro in this way will
require extensive clinical testing to determine if they
are capable of boosting pDC function and restoring immune
competence in cHCV disease. To date, one class C ODN
CpG10101 (Actilon
 ; Coley Pharmaceutical Group Inc.,
Wellesley, MA, USA) has undergone clinical testing in cHCV
patients refractory to conventional combination therapy.
Although Actilon
  did not enhance sustained viral clear-
ance in this cohort [44,45], these subjects who had shown
resistance to previous exogenous interferon based therapy
may have been destined to fail treatment with an immuno-
modulator that works by inducing endogenous interferons.
Critically, the efﬁcacy of type C CpGs in treatment-naı ¨ve HCV
patients remains untested.
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